Stephen Graham is co-chair of Fenwick & West’s Life Sciences Practice and Managing Partner of the Seattle Office.
Stephen concentrates in the areas of private and public mergers and acquisitions, public offerings, private placements, and corporate governance matters, including advising boards of directors and audit, compensation and nominating/corporate governance committees, preparation and filing of periodic SEC reports, and other securities law compliance, including Sarbanes-Oxley Act matters and disclosure issues with respect to Rule 10b-5 and Regulation FD.
His diverse practice is focused on the representation of emerging and established high growth companies, essentially serving as an extension of the senior management teams and boards of directors. Stephen has represented companies and investment banks in numerous initial public offerings, a wide variety of merger and acquisition transactions, and private offerings of debt and equity.
Stephen has been recognized by Chambers USA as one of the top corporate and mergers and acquisitions lawyers in Washington. He is also a “Super Lawyer” award recipient, 2000 - 2014, is listed in Who’s Who in America by Marquis Biographical Reference, has been recognized as one of The Best Lawyers in America, and is a member of Pi Sigma Alpha. Stephen was also recognized as a “Life Sciences Star” for his outstanding transactional work in Euromoney’s LMG Life Sciences 2012 and 2013.
In 2011, Stephen was appointed co-chairperson of the Securities and Exchange Commission’s Advisory Committee on Small and Emerging Companies and continues to serve in that position. In 2015, he was named "one of the 19 most influential people in D.C. who can affect your small business" by The Washington Post for his role with the SEC. He is active in community affairs, currently serving on the Board of Directors of the Fred Hutchinson Cancer Research Center, the Institute for Systems Biology and the Washington Biotechnology & Biomedical Association, where he serves on the Executive Committee. He is also a member of the Bank of Montreal Financial Group Washington Advisory Board and serves on the Editorial Board of eHealth Law & Policy.
Prior to joining Fenwick & West, Stephen was a corporate partner with Orrick, Herrington & Sutcliffe LLP, where he was the chair of the global Corporate Practice Group.
- Accelerator Corporation
- Cardeas Pharma Corp.
- Cardiac Dimensions, Inc.
- Institute for Systems Biology
- Marine Construction Technologies
- NaviSonics, Inc.
- Omeros Corporation
- ProNAi Therapeutics, Inc.
- Resolute Medical, Inc.
- Sound Pharmaceuticals, Inc.
- Speshio, Inc.
- Teikoku Pharma USA, Inc.
- Theraclone Sciences, Inc.
- VentiRx Pharmaceuticals, Inc.
- Vicis, Inc.
Represented the following corporations until their acquisition:
- Amnis Corporation
- Corixa Corporaiton
- Corus Pharma, Inc.
- ICOS Corporation
- Immunex Corporation
- InControl, Inc.
- LipoSonix, Inc.
- SonoSite, Inc.
- WatchGuard Technologies, Inc.
- ZymoGenetics, Inc.